Allena Pharmaceuticals Announces Interim Results from Study 206 of Reloxaliase in High Risk Patients with Advanced Oxalate ...
-- Substantial Treatment Effect Observed in Patients with Enteric Hyperoxaluria, Including Robust Reductions in Both Urine and Plasma Oxalate – -- Reloxaliase Well-Tolerated Over 12 Weeks of Dosing -- -- Detailed Results to be Presented at OHF …